(Photo Courtesy: www.reckless-addictions.com)
Under the terms of agreement, which includes a research collaboration with Roche's research and early development organization to further extend Curadev's findings, Curadev will receive an upfront payment of $25 million, and will be eligible to receive up to $530 million in milestone payments based on achievement of certain predetermined events and sales levels, as well as escalating royalties, potentially reaching double digits for the first product from the collaboration developed and commercialized by Roche.
The agreement covers the development of the lead pre-clinical immune tolerance inhibitor and a research collaboration with Roche's research and early development organization to further explore the IDO and TDO pathways.
Curadev would also be eligible for milestones and royalties on any additional products resulting from the research collaboration.
Roche will fund future research, development, manufacturing and commercialization costs and will also provide additional research funding to Curadev for support of the research collaboration.
IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) are enzymes that mediate cancer-induced immune suppression.